Identification of Candida spp. in the oral cavity in patients with malignant diseases

Irena Glažar; Jelena Prpić; Miranda Muhvić Urek; Sonja Pezelj-Ribarić

doi:10.2298/VSP151125295G

Irena Glažar University of Rijeka, Faculty of Medicine, Clinical Hospital Centre, Department of Oral Medicine and Periodontology, Rijeka, Croatia
Jelena Prpić University of Rijeka, Faculty of Medicine, Clinical Hospital Centre, Department of Oral Medicine and Periodontology, Rijeka, Croatia
Miranda Muhvić Urek University of Rijeka, Faculty of Medicine, Clinical Hospital Centre, Department of Oral Medicine and Periodontology, Rijeka, Croatia
Sonja Pezelj-Ribarić University of Rijeka, Faculty of Medicine, Clinical Hospital Centre, Department of Oral Medicine and Periodontology, Rijeka, Croatia

DOI: https://doi.org/10.2298/VSP151125295G

Keywords: candida, candida albicans, mouth, neoplasms, microbiological techniques, candidiasis, oral,

Abstract

Background/Aim. Oral candidiasis frequently causes discomfort in patients treated for malignant diseases, acting as well as a potential source of systemic infection. This disease may present itself through different clinical manifestations of both acute or chronic type. The aim of this study was to identify different Candida species from oral cavities of patients suffering from malignant diseases. Methods. Thirty patients admitted to the hospital for diagnostics/treatment of malignant diseases were included in this investigation. All subjects had visible changes of oral mucosa in the form of pseudomembranes and inflammation corresponding to oral candidiasis. Control group included 30 non-hospitalized patients diagnosed with candidiasis. Diagnosis of oral candidiasis was confirmed in all patients by microbiological analysis of tongue swabs. For microbiota identification, three different tests were used: germination test, fungal growth test on corn meal agar, and biochemical identification with commercially available ID 32 C kit (bio-Merieux, Marcy-l´Etoile, France). Results. Out of 30 isolates collected from hospitalized patients, 90% was related to Candida albicans, 7% was identified as Candida kefyr, and 3% as Candida famata. In samples collected from non-hospitalized controls, we isolated Candida albicans in 90% of the cases, in 7% Candida kefyr, while in 3% we identified Candida glabrata. Conclusion. Based on this investigation, oral candidiasis in patients treated with radiotherapy and chemotherapy is mainly caused by Candida albicans. It is to be expected that Candida albicans will remain the most significant causative agent of oral candidasis, although we must bear in mind the possibility of other pathogenic species.

References

Garcia-Cuesta C, Sarrion-Pérez MG, Bagán JV. Current treatment of oral candidiasis: A literature review. J Clin Exp Dent 2014; 6(5): e576−82.

Canković M, Bokor-Bratić M. Candida albicans infection in pa-tients with oral squamous cell carcinoma. Vojnosanit Pregl 2010; 67(9): 766−70. (Serbian)

Dineshshankar J, Sivakumar M, Karthikeyan M, Udayakumar P, Shanmugam KT, Kesavan G. Immunology of oral candidiasis. J Pharm Bioall Sci 2014; 6(Suppl 1): 9−12.

Byadarahally Raju S, Rajappa S. Isolation and identification of Candida from the oral cavity. ISRN Dent 2011; 2011: 487921.

Krishnan PA. Fungal infections of the oral mucosa. Indian J Dent Res 2012; 23(5): 650−9.

Kurnatowski P, Moqbil S, Kaczmarczyk D. Signs, symptoms and the prevalence of fungi detected from the oral cavity and phar-ynx of radiotherapy subjects with head and neck tumors, and their susceptibility to chemotherapeutics. Ann Parasitol 2014; 60(3): 207−13.

Singh A, Verma R, Murari A, Agrawal A. Oral candidiasis: An overview. J Oral Maxillofac Pathol 2014; 18(Suppl 1): S81−5.

Barker BF, Barker GJ. Oral complications and management of cancer chemotherapy. Northwest Dent 1990; 69(6): 23−6.

Wong HM. Oral Complications and Management Strategies for Patients Undergoing Cancer Therapy. Sci World J 2014; 2014: 14.

Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G. Invasive fungal infections in the ICU: How to approach, how to treat. Molecules 2014; 19(1): 1085−119.

Farah CS, Lynch N, McCullough MJ. Oral fungal infections: an update for the general practitioner. Aust Dent J 2010; 55(Suppl 1): 48−54.

Ramani R, Gromadzki S, Pincus DH, Salkin IF, Chaturvedi V. Ef-ficacy of API 20C and ID 32C systems for identification of common and rare clinical yeast isolates. J Clin Microbiol 1998; 36(11): 3396−8.

Donnelly PJ, Bellm LA, Epstein JB, Sonis ST, Symonds PR. Antimi-crobial therapy to prevent or treat oral mucositis. Lancet Infect Dis 2003; 3(7): 405−12.

Richardson MD. Changing patterns and trends in systemic fun-gal infections. J Antimicrob Chemother 2005; 56 Suppl 1: i5−i11.

Ruhnke M, Maschmeyer G. Management of mycoses in patients with hematologic disease and cancer: Review of the literature. Eur J Med Res 2002; 7(5): 227−35.

Paterson PJ, McWhinney PH, Potter M, Kibbler CC, Prentice HG. The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic pa-tients. Br J Haematol 2001; 112(1): 175−80.

Soysa NS, Samaranayake LP, Ellepola AN. Cytotoxic drugs, ra-diotherapy and oral candidiasis. Oral Oncol 2004; 40(10): 971−8.

Kostler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: Options for prevention and treatment. CA Cancer J Clin 2001; 51(5): 290−315.

Nicolatou-Galitis O, Dardoufas K, Markoulatos P, Sotiropoulou-Lontou A, Kyprianou K, Kolitsi G, et al. Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucosi-tis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash. J Oral Pathol Med 2001; 30(8): 471−80.

Hofer E, Jensen SB, Pedersen AM, Bardow A, Nauntofte B. Oral Microflora in Patients with Salivary Gland Hypofunction. Oral Biosci Med 2004; 1(2): 93−108.

Martinez EM, Bagan JV, Jimnez Y, Scully C. Evaluation of dental health and the need for dental treatment prior to radiotherapy in eighty-three patients with head and neck cancer. Oral Biosci Med 2004; 1(3): 181−5.

Xu L, Zhang H, Liu J, Chen X. Investigation of the oral infec-tions and manifestations seen in patients with advanced can-cer. Pak J Med Sci 2013; 29(5): 1112−5.

Bulacio L, Paz M, Ramadán S, Ramos L, Pairoba C, Sortino M, et al. Oral infections caused by yeasts in patients with head and neck cancer undergoing radiotherapy. Identification of the yeasts and evaluation of their antifungal susceptibility. J Mycol Med 2012; 22(4): 348−53.

Arendrup MC. Candida and candidaemia. Susceptibility and ep-idemiology. Dan Med J 2013; 60(11): B4698.

Swoboda-Kopec E, Kawecki D, Wroblewska M, Krawczyk M, Luczak M. Epidemiology and susceptibility to antifungal agents of fungi isolated from clinical specimens from patients hospital-ized in the Department of General and Liver Surgery of the Medical University of Warsaw. Transplant Proc 2003; 35(6): 2298−303.

Patel A, Gruber P. Severe infections in neutropenic patients. Curr Opin Crit Care 2015; 21(6): 586−92.

Dufresne SF, Marr KA, Sydnor E, Staab JF, Karp JE, Lu K, et al. Epidemiology of Candida kefyr in patients with hematologic malignancies. J Clin Microbiol 2014; 52(6): 1830−7.

Krcmery V, Barnes AJ. Non-albicans Candida spp. Causing fun-gaemia: Pathogenicity and antifungal resistance. J Hosp Infect 2002; 50(4): 243−60.

Morii D, Seki M, Binongo JN, Ban R, Kobayashi A, Sata M, et al. Distribution of Candida species isolated from blood cultures in hospitals in Osaka, Japan. J Infect Chemother 2014; 20(9): 558−62.

Redding SW, Dahiya MC, Kirkpatrick WR, Coco BJ, Patterson TF, Fothergill AW, et al. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97(1): 47−52.